Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Quercetin and ferulic acid antioxidants aggravate kidney cancer in severely diabetic rats

Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants - including those renowned for their apparent ability to prevent cancer - may actually aggravate or even cause cancer in some individuals. Their recommendation follows a study in which two such antioxidants - quercetin and ferulic acid - appeared to aggravate kidney cancer in severely diabetic laboratory rats. The study appears in ACS' bi-weekly Journal of Agricultural and Food Chemistry.

9 Sep 2010

Two genes linked to ovarian clear cell carcinoma

Scientists at the Johns Hopkins Kimmel Cancer Center have identified two genes whose mutations appear to be linked to ovarian clear cell carcinoma, one of the most aggressive forms of ovarian cancer. Clear cell carcinoma is generally resistant to standard therapy.

9 Sep 2010

BC gynecologists initiate campaign to reduce ovarian cancer mortality

Gynecologic oncologists with the Ovarian Cancer Research Program at Vancouver General Hospital (VGH) and the BC Cancer Agency have begun an important campaign that will reduce deaths from ovarian cancer.

9 Sep 2010

ARID1A gene links ovarian cancer to endometriosis

Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis.

9 Sep 2010

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo Company announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically integrate this product with their own API.

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

Researchers develop new RNA molecule approach to kill cancer cells

Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues uses small RNA molecules that can be programmed to attack only specific cancer cells then, by changing shape, those molecules cause the cancer cells to self destruct.

8 Sep 2010

Tikcro reports $3.2 million net loss for second-quarter 2010

Tikcro Technologies Ltd. today reported results for the second quarter and six months ended June 30, 2010.

7 Sep 2010

MSKCC develops new prediction tool to calculate risk for DCIS recurrence after breast-conserving surgery

The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. Standard treatments following surgery include radiation therapy and hormone treatment.

4 Sep 2010

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Celsion Corporation, a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, "New Thermal Sensitive Carboplatin Liposomes for Cancer".

3 Sep 2010

Abbott RealTime HBV assay receives marketing approval from FDA

Abbott announced today it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.

2 Sep 2010

Consuming variety of fruits, vegetables may decrease squamous cell lung cancer risk: Study

Adding a variety of vegetables to one's diet may help decrease the chance of getting lung cancer, and adding a variety of fruits and vegetables may decrease the risk of squamous cell lung cancer, especially among smokers.

2 Sep 2010

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).

27 Aug 2010

JVIR supplement to review thermal ablation usage in treating cancer

The unprecedented growth and promise of using thermal ablation to target and kill cancer is the subject of the Journal of Vascular and Interventional Radiology's August supplement, "Thermal Ablation 2010 At the Crossroads of Past Success, Current Goals and Future Technology."

27 Aug 2010

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver.

26 Aug 2010

CreAgri receives patent for Hydroxytyrosol for skin damage by UV exposure

CreAgri, Inc. announced today that the company has received a Patent by the Australian Patent Office, Patent Number 2003249719, which covers the protective effects provided by Hydroxytyrosol against skin damage caused by UV exposure.

26 Aug 2010

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.

26 Aug 2010

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.

26 Aug 2010

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.

25 Aug 2010

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies.

24 Aug 2010

Carcinoma News and Research

Further Reading

Quercetin and ferulic acid antioxidants aggravate kidney cancer in severely diabetic rats

Two genes linked to ovarian clear cell carcinoma

BC gynecologists initiate campaign to reduce ovarian cancer mortality

ARID1A gene links ovarian cancer to endometriosis

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Researchers develop new RNA molecule approach to kill cancer cells

Tikcro reports $3.2 million net loss for second-quarter 2010

MSKCC develops new prediction tool to calculate risk for DCIS recurrence after breast-conserving surgery

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Abbott RealTime HBV assay receives marketing approval from FDA

Consuming variety of fruits, vegetables may decrease squamous cell lung cancer risk: Study

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

JVIR supplement to review thermal ablation usage in treating cancer

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

CreAgri receives patent for Hydroxytyrosol for skin damage by UV exposure

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News